Literature DB >> 1731035

Cyclooxygenase dependency of the renovascular actions of cytochrome P450-derived arachidonate metabolites.

M A Carroll1, M P Garcia, J R Falck, J C McGiff.   

Abstract

The renovascular effects of cytochrome P450-dependent arachidonic acid (P450-AA) metabolites synthesized by rat and rabbit kidneys were studied in the rabbit isolated kidney under conditions of constant flow and examined for their dependency on cyclooxygenase relative to their expression of vasoactivity. Kidneys were perfused with Krebs-Henseleit solution, and perfusion pressure was raised to levels of 90 to 110 mm Hg with the addition of 2 to 3 microM phenylephrine to the perfusate. Close arterial injection of 1 to 20 micrograms of 5,6-, 8,9- and 11,12-epoxyeicosatrienoic acid (EET) dose-dependently decreased perfusion pressure. The 5,6-EET was the most potent and the only epoxide dependent on cyclooxygenase for expression of vasoactivity, being inhibited by indomethacin (2.8 microM). In contrast, 14,15-EET resulted in dose-dependent increases in perfusion pressure. The vasodilator effects of the omega- and omega-1 oxidation products, 20-hydroxyeicosatetraenoic acid (HETE) and the stereoisomers of 19-HETE, were also inhibited by indomethacin. Furthermore, the renal vasodilator responses to 5,6-EET were not inhibited by either superoxide dismutase (10 U) or catalase (40 U) and, therefore, were unrelated to the formation of oxygen radicals generated during transformation of the epoxide by cyclooxygenase. As 5,6-EET and 19- and 20-HETE are synthesized by the renal tubules and can affect movement of salt and water, expression of vasoactivity by P450-dependent arachidonic acid metabolites, and after release from a nephron segment, may represent a mechanism that couples altered renal tubular function to appropriate changes in local blood flow.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1731035

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  30 in total

1.  HET0016, a potent and selective inhibitor of 20-HETE synthesizing enzyme.

Authors:  N Miyata; K Taniguchi; T Seki; T Ishimoto; M Sato-Watanabe; Y Yasuda; M Doi; S Kametani; Y Tomishima; T Ueki; M Sato; K Kameo
Journal:  Br J Pharmacol       Date:  2001-06       Impact factor: 8.739

Review 2.  A new class of lipid mediators: cytochrome P450 arachidonate metabolites.

Authors:  M A Carroll; J C McGiff
Journal:  Thorax       Date:  2000-10       Impact factor: 9.139

3.  Eicosanoid excretion in hepatic cirrhosis. Predominance of 20-HETE.

Authors:  D Sacerdoti; M Balazy; P Angeli; A Gatta; J C McGiff
Journal:  J Clin Invest       Date:  1997-09-01       Impact factor: 14.808

4.  Possible role of P-450 metabolite of arachidonic acid in vasodilator mechanism of angiotensin II type 2 receptor in the isolated microperfused rabbit afferent arteriole.

Authors:  S Arima; Y Endo; H Yaoita; K Omata; S Ogawa; K Tsunoda; M Abe; K Takeuchi; K Abe; S Ito
Journal:  J Clin Invest       Date:  1997-12-01       Impact factor: 14.808

5.  NS-398 reverses hypotension in endotoxemic rats: contribution of eicosanoids, NO, and peroxynitrite.

Authors:  Bahar Tunctan; Ayse Nihal Sari; Meltem Kacan; Demet Unsal; C Kemal Buharalioglu; Seyhan Sahan-Firat; Belma Korkmaz; John R Falck; Kafait U Malik
Journal:  Prostaglandins Other Lipid Mediat       Date:  2012-09-05       Impact factor: 3.072

6.  A synthetic analogue of 20-HETE, 5,14-HEDGE, reverses endotoxin-induced hypotension via increased 20-HETE levels associated with decreased iNOS protein expression and vasodilator prostanoid production in rats.

Authors:  Tuba Cuez; Belma Korkmaz; C Kemal Buharalioglu; Seyhan Sahan-Firat; John Falck; Kafait U Malik; Bahar Tunctan
Journal:  Basic Clin Pharmacol Toxicol       Date:  2009-12-07       Impact factor: 4.080

7.  5,14-HEDGE, a 20-HETE mimetic, reverses hypotension and improves survival in a rodent model of septic shock: contribution of soluble epoxide hydrolase, CYP2C23, MEK1/ERK1/2/IKKβ/IκB-α/NF-κB pathway, and proinflammatory cytokine formation.

Authors:  Bahar Tunctan; Belma Korkmaz; Ayse Nihal Sari; Meltem Kacan; Demet Unsal; Mehmet Sami Serin; C Kemal Buharalioglu; Seyhan Sahan-Firat; Tuba Cuez; Wolf-Hagen Schunck; John R Falck; Kafait U Malik
Journal:  Prostaglandins Other Lipid Mediat       Date:  2013-02-27       Impact factor: 3.072

8.  Failure to upregulate the adenosine2A receptor-epoxyeicosatrienoic acid pathway contributes to the development of hypertension in Dahl salt-sensitive rats.

Authors:  Elvira L Liclican; John C McGiff; John R Falck; Mairéad A Carroll
Journal:  Am J Physiol Renal Physiol       Date:  2008-10-01

9.  Combined therapy with COX-2 inhibitor and 20-HETE inhibitor reduces colon tumor growth and the adverse effects of ischemic stroke associated with COX-2 inhibition.

Authors:  Yi Zhang; Md Nasrul Hoda; Xuan Zheng; Weiguo Li; Pengcheng Luo; Krishna Rao Maddipati; Tsugio Seki; Adviye Ergul; Mong-Heng Wang
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2014-07-02       Impact factor: 3.619

Review 10.  Epoxyeicosatrienoic Acids and 20-Hydroxyeicosatetraenoic Acid on Endothelial and Vascular Function.

Authors:  J D Imig
Journal:  Adv Pharmacol       Date:  2016-05-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.